AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06041893
Drug: ATG-LDPTCy
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antithymocyte globulin with low dose post-transplant cyclophosphamide
Trial: NCT06393166
Drug: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
Trial: NCT06631300
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
Trial: NCT05242458
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
Trial: NCT06318260
Drug: Dobutrex
RxNorm normalized name: Dobutrex
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
Trial: NCT05498467
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg Anakinra injections s.c.
Trial: NCT05498467
Drug: Sodium Chloride 9mg/ml Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 mg Sodium Chloride injections s.c.
Trial: NCT04499131
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
Trial: NCT05141357
Drug: HBI-8000 in combination with pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
Trial: NCT06411665
Drug: Oliceridine
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
Trial: NCT06411665
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
Trial: NCT05481489
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine Sulfate 0.05% Ophthalmic Solution
Trial: NCT05838664
Drug: VKA
RxNorm normalized name: METHYLPHENIDATE HCL (AVKARE) 18MG SA TAB
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AF patients who received VKA
Trial: NCT05838664
Drug: apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AF patients who received apixaban
Trial: NCT05838664
Drug: rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AF patients who received rivaroxaban
Trial: NCT05838664
Drug: dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF patients who received dabigatran
Trial: NCT04945694
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia
Trial: NCT04945694
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane anesthesia
Trial: NCT04945694
Drug: Atracurium
RxNorm normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atracurium
Trial: NCT05193851
Drug: ricolinostat
RxNorm normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period.
Trial: NCT05121948
Drug: HC-7366
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
Trial: NCT00001999
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02894307
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In patients with mechanical valves and unstable INR
Trial: NCT00002203
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002203
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002203
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05225363
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04968574
Drug: taladegib
RxNorm normalized name: Taladegib
DrugBank: Taladegib (DB12550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hedgehog pathway inhibitor dosed once daily
Trial: NCT05668286
Drug: A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)
RxNorm normalized name: magnesium hydroxide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
Trial: NCT05207735
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles.
Trial: NCT06711094
Drug: Dalpiciclib
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator
Trial: NCT05097443
Drug: Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD.
Trial: NCT05021770
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg or 200mg orally daily
Trial: NCT05021770
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP2D
Trial: NCT05021770
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
Trial: NCT04843761
Drug: Remdesivir Placebo
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Trial: NCT04843761
Drug: Aviptadil Placebo
DrugBank: Aviptadil (DB06260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
Trial: NCT06549556
Drug: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
RxNorm normalized name: COLOSTRUM
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
Trial: NCT06714266
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib
Trial: NCT06711900
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT06711900
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Infusion
Trial: NCT06711900
Drug: carboplatin or cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05052983
Drug: Nemolizumab
RxNorm normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
Trial: NCT06712030
Drug: Sacubitril / Valsartan
RxNorm normalized name: sacubitril / valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)
Trial: NCT06714604
Drug: FOLFIRINOX or gemcitabine-nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 months if treatment
Trial: NCT06714604
Drug: FOLFIRINOX or gemcitabine-nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 months of treatment
Trial: NCT00000913
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000913
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000913
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06712199
Drug: oxalidine
RxNorm normalized name: 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:
Trial: NCT04312789
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06380348
Drug: JMT101 Injection
RxNorm normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
Trial: NCT05231460
Drug: non-narcotic regimen with TAP block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Trial: NCT05231460
Drug: non-narcotic regimen with no TAP block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Trial: NCT06380348
Drug: Osimertinib tablet
RxNorm normalized name: Osimertinib Tablets
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib 160mg once po everyday
Trial: NCT05299008
Drug: Bethanechol
RxNorm normalized name: Bethanechol
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
Trial: NCT06380348
Drug: Cisplatin injection
RxNorm normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
Trial: NCT06380348
Drug: Pemetrexed injection
RxNorm normalized name: pemetrexed Injection
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
Trial: NCT05594407
Drug: dexmedetomidine-ketamine-lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
Trial: NCT05144217
Drug: 2x 140 mg per day
RxNorm normalized name: deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 capsule per day of silimarit
Trial: NCT04410913
Drug: Psilocybin plus Visual Healing Set and Setting
RxNorm normalized name: dimethicone
DrugBank: Psilocybin (DB11664)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
Trial: NCT04410913
Drug: Psilocybin plus Standard Set and Setting
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
Trial: NCT05088057
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
Trial: NCT05088057
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
Trial: NCT05988879
Drug: Peginterferon alfa-2b Injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
Trial: NCT06507657
Drug: empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Trial: NCT05479045
Drug: Toripalimab-tpzi
RxNorm normalized name: toripalimab-tpzi
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
Trial: NCT05971537
Drug: conventional IP antibiotics
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
Trial: NCT06164834
Drug: Clopidogrel 75 mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75 mg tablet
Trial: NCT06164834
Drug: Tegoprazan 25 mg
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 25 mg tablet
Trial: NCT06164834
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg tablet
Trial: NCT06182969
Drug: APG-2575
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take orally once daily (QD) for 12 weeks.